Bausch + Lomb Corp

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bausch + Lomb Corp reports stellar Q2 performance and raises guidance

Bausch + Lomb Corp's Q2 2024 earnings call showcased robust performance, with revenue growth, margin improvement, and raised guidance reflecting a strong outlook.
The company's emphasis on innovation, operational excellence, and long-term growth strategies highlights a commitment to sustained success and shareholder value.
While facing challenges in specific areas and competitive markets, Bausch + Lomb's focus on balancing growth, margins, and investments positions it well for future opportunities.

Bausch + Lomb Corp (BLCO) reports strong Q3 earnings and raises full-year guidance amidst strategic growth focus

Bausch + Lomb Corp (BLCO) delivered a strong Q3 performance with revenue growth, margin expansion, and raised full-year guidance, reflecting a solid financial outlook.
The company's focus on execution, product launches, and strategic investments is driving growth and profitability across segments, showcasing a resilient business strategy.
While challenges like market dynamics and operational complexities persist, opportunities in market expansion, innovation, and strategic partnerships offer avenues for sustained growth.
Overall, Bausch + Lomb Corp (BLCO) is well-positioned for continued success through its commitment to growth, innovation, and operational excellence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VAUGHAN, ON and HEIDELBERG, Germany , July 7, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced the submission of a New Drug Application (NDA) at the end of June to the U.S. Food and Drug Administration (FDA) seeking approval for NOV03 (perfluorohexyloctane), an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). "We are thrilled to have the potential to advance the care of people suffering from dry eye disease associated with Meibomian gland dysfunction.

Bausch + Lomb and Novaliq Announce Submission of New Drug Application for Investigational Treatment NOV03 (Perfluorohexyloctane)

Five Presentations Will Highlight Findings from the XIPERE® Pivotal Phase 3 Program VAUGHAN, ON , July 6, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that five presentations highlighting data from the XIPERE® (triamcinolone acetonide injectable suspension) pivotal Phase 3 program will be presented at the American Society of Retina Specialists (ASRS) 40th annual scientific meeting, which will take place in New York from July 13-16, 2022. The presentations will include a new post-hoc analysis of the pivotal Phase 3 trial (PEACHTREE) evaluating outcomes following treatment with XIPERE® in patients with macular edema associated with chronic uveitis.

Bausch + Lomb Announces Scientific Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) to be Presented During the American Society of Retina Specialists Annual Scientific Meeting

VAUGHAN, ON , June 23, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, is pleased to announce that it has expanded its Board of Directors (the "Board") to add two designees to the Board from Carl C. Icahn and affiliated entities (the "Icahn Group").

Bausch + Lomb Announces Brett Icahn and Gary Hu Have Been Appointed to its Board of Directors

New Family of Customizable Soft Contact Lenses Designed to Meet the Needs of More Patients VAUGHAN, ON , June 13, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Revive™ custom soft contact lenses, a new family of customizable soft contact lenses. Available in spherical, toric, multifocal and multifocal toric options, Revive™ custom soft lenses are designed to meet the vision needs of more patients, including those with high or unique prescriptions.

Bausch + Lomb Announces the U.S. Launch of Revive™ Custom Soft Contact Lenses

Bausch Health Companies Inc

BHC's stake in BLCO that is set to be distributed to shareholders is worth more than the current market capitalization of the entirety of BHC, giving investors a compelling return. The BLCO spinoff and Solta Medical IPO proceeds are sufficient for BHC to shoulder its approximately $20 billion debt load.

Bausch Health Companies: 2022's Most Compelling Special Situation

Recent financial performance reported by Bausch + Lomb has been encouraging from a sales perspective. However, the company's bottom line is facing continued difficulties.

Bausch + Lomb: Shares Deserve Some Upside

Bausch + Lomb Corporation (NYSE:BLCO ) Q1 2022 Results Conference Call June 8, 2022 8:00 AM ET Company Participants Allison Ryan - Director, IR Joe Papa - Chairman, CEO Sam Eldessouky - CFO Conference Call Participants Cecilia Furlong - Morgan Stanley Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Pito Chickering - Deutsche Bank Robbie Marcus - JP Morgan Yatin Suneja - Guggenheim Partners Joanne Wuensch - Citi Zach Weiner - Jefferies Ken Cacciatore - Cowen Operator Good morning, and welcome to the Bausch + Lomb's First Quarter 2022 Earnings Call. [Operator Instructions] Please note, this event is being recorded.

Bausch + Lomb Corporation (BLCO) CEO Joe Papa on Q1 2022 Results - Earnings Call Transcript

Bausch + Lomb Corp. BLCO, -3.16% reported Wednesday first-quarter profit that topped expectations but revenue that came up short, as growth in vision care and surgical segment revenue was partially offset by declines in ophthalmic pharmaceuticals revenue. The contact lens and surgical device maker's stock was still inactive in premarket trading.

Bausch + Lomb tops profit expectations but revenue comes up shy

First-Quarter 2022 Financial Results Revenues of $889 Million GAAP Net Income of $20 Million Adjusted EBITDA (non-GAAP) 1  of $170 Million Bausch + Lomb Commenced Trading Under "BLCO" Ticker Reported Revenues Grew 1%, and Organic Revenues1, 2  Grew 5% VAUGHAN, ON , June 8, 2022 /PRNewswire/ -- Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company" or "we"), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2022 financial results. "In the first quarter, Bausch + Lomb delivered organic revenue1,2 growth, driven by our two largest segments, Vision Care and Surgical," said Joseph C.

Bausch + Lomb Announces First-Quarter 2022 Results and Provides 2022 Guidance

Seven Presentations Will Include Unique Research on the New Biotrue® Hydration Plus Multi-Purpose Solution and Biotrue® Hydration Boost Lubricant Eye Drops Company to Also Host Several Sponsored Education Events VAUGHAN, ON , June 6, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that seven presentations will feature unique research on new Biotrue® Hydration Plus Multi-Purpose Solution and Biotrue® Hydration Boost lubricant eye drops during the American Optometric Association's Optometry's Meeting ePosters Virtual Event, which is taking place from June 7-8, 2022. The company will also host several sponsored education events at the Optometry's Meeting in Chicago from June 15-18, 2022.

Bausch + Lomb Announces Scientific Data on Latest Biotrue® Products to be Presented at American Optometric Association's Optometry's Meeting

Campaign Includes Educational Social Media Posts to Broaden Patient Awareness of Cataract Surgery and Care During Cataract Awareness Month VAUGHAN, ON , June 2, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced a new social media campaign designed to raise awareness around cataracts and the importance of routine screening for this treatable condition. The campaign will run throughout June during Cataract Awareness Month.

New Social Media Campaign From Bausch + Lomb Aims to Raise Awareness that Cataracts Don't Wait

New Formula Provides More Moisture1 on Contact Lenses for Patients Now Available at Most Major U.S. Retailers VAUGHAN, ON , June 2, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Biotrue® Hydration Plus Multi-Purpose Solution. The new contact lens solution, which is formulated with bio-inspired ingredients, provides more moisture on lenses1, excellent cleaning and a triple disinfectant system that helps deliver exceptional disinfection.

Bausch + Lomb Announces the U.S. Launch of Biotrue® Hydration Plus Multi-Purpose Solution

PepGen Inc

It's hard to know what to buy and what to sell with market conditions the way they are but it looks like a good time to start nibbling on these two recent IPOs. Bausch + Lomb (NYSE: BLCO) and PepGen (NASDAQ: PEPG) both IPOd in 2022 and have seen their shares plummet in the wake of the offering, not because they are poor companies or bad investments but simply because the market conditions changed.

It's Time To Nibble On These Two Recent IPOs

VAUGHAN, Ontario , May 25, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2022 financial results on Wednesday, June 8, 2022. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m.

Bausch + Lomb Will Release First-Quarter 2022 Financial Results on June 8

LUMIFY® is Canada's First and Only Over-the-Counter Eye Drop with Low-Dose Brimonidine for the Relief of Eye Redness VAUGHAN, ON , May 24, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved LUMIFY® (brimonidine tartrate ophthalmic solution 0.025% w/v), the first and only over-the-counter (OTC) eye drop developed with low-dose brimonidine tartrate to relieve redness of the eye due to minor eye irritations for adults.1 "With Health Canada's approval of LUMIFY®, we are excited to be able to now offer Canadians a new option to help relieve their red, irritated eyes," said Joe Gordon, president, Global Consumer, Surgical and Vision Care. "Bausch + Lomb is dedicated to meeting the needs of eye care professionals and their patients, and we're proud to bring LUMIFY® forward as an example of our continued commitment to developing innovative eye health products.

Bausch + Lomb Receives Health Canada Approval of LUMIFY® Redness Reliever Eye Drops

VAUGHAN, ON , May 16, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, has today filed its financial statements for the quarter ended March 31, 2022, in accordance with applicable Canadian securities laws. The Company intends to file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 on or before June 20, 2022 (being the first business day that is 45 days from the date of effectiveness of Bausch + Lomb's Registration Statement on Form S-1, as amended, filed in connection with the Company's recent initial public offering) in compliance with the U.S. Securities and Exchange Commission rules.

Bausch + Lomb Corporation Files Financial Statements for the First Quarter of 2022

VAUGHAN, ON , May 13, 2022 /PRNewswire/ -- Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the RBC Capital Markets Global Healthcare Conference on May 17, 2022, at 9:30 a.m.

Bausch + Lomb Announces Participation at the RBC Capital Markets Global Healthcare Conference

Survey Reinforces Need for Innovative Therapies, Including Options Administered Through Suprachoroidal Space VAUGHAN, ON , May 12, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today released findings from a survey designed to gain an understanding of retina specialists' need for a new treatment option for patients with macular edema associated with noninfectious uveitis and the new drug delivery method in which treatment is administered via the suprachoroidal space. Approximately 85 percent of retina specialists surveyed considered drug delivery via suprachoroidal space as an option for patients with macular edema associated with noninfectious uveitis, approximately 84 percent have high interest in learning more about it and more than nine out of 10 said alternatives are needed to treat patients with this condition.

New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis

Bausch Health has seen a very tough 2022 as investors price in higher interest rates on its massive debt load and softer IPO of its subsidiary Bausch + Lomb. These are not encouraging trends, but the valuation reset has been enormous, potentially creating an opportunistic investment opportunity here.

Bausch Health Companies: Headwinds, Again

LAVAL, QC and VAUGHAN, ON , May 10, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb") and Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") today announced the closing of the initial public offering ("IPO") of Bausch + Lomb. A wholly owned subsidiary of Bausch Health (the "Selling Shareholder") sold 35,000,000 common shares at a public offering price of $18.00 per share for aggregate gross proceeds of $630 million, before deducting underwriting commissions and estimated offering expenses.

Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions

Here's what investors in Bausch + Lomb may want to know about the highly anticipated BLCO stock IPO, which took place today. The post BLCO Stock: 7 Things to Know About the Bausch + Lomb IPO Today appeared first on InvestorPlace.

BLCO Stock: 7 Things to Know About the Bausch + Lomb IPO Today

(Reuters) -Bausch + Lomb was valued at $6.48 billion in its U.S. market debut on Friday as the eye-care company's shares opened nearly 3% above an offer price that was well below the targeted range.

Bausch + Lomb valued at $6.5 billion after stock ticks up in NYSE debut

Bausch + Lomb Begins Trading under "BLCO" on NYSE and TSX Fully Integrated Eye Health Business Sets Its Sights On Helping the World See Better To Live Better VAUGHAN, ON , May 6, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today launched as a publicly traded company focused on protecting and enhancing the gift of sight for millions of people around the world when it began trading under the "BLCO" symbol on the New York Stock Exchange and Toronto Stock Exchange.1 Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/9046751-bausch-lomb-corporation-launches-as-publicly-traded-company/ "Today marks a tremendous milestone for Bausch + Lomb and an important step forward on the path to an independent company focused on eye health," said Joseph C. Papa, chairman and CEO, Bausch + Lomb.

BAUSCH + LOMB CORPORATION LAUNCHES AS A PUBLICLY TRADED COMPANY

Bausch + Lomb Corp.'s stock BLCO, +5.39% debuted Friday with a slight gain, which helped justify the disappointing pricing overnight of the lenses and medical devices maker's initial public offering. The company said late Thursday that its IPO priced at $18 a share, which was well below the expected range of between $21 and $24, as the company raised $630 million.

Bausch + Lomb stock opens with a slight gain, to value the company at about $6.5 billion

Bausch + Lomb's busted IPO will cost its parent billions in write-downs. It also signals trouble ahead for the IPO market and venture backed startups

News for Bausch + Lomb Corp Stock (BLCO)